Literature DB >> 30033110

Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers.

Wioleta M Zelek1, Claire L Harris2, B Paul Morgan3.   

Abstract

Complement assays have for many years utilised buffers based on barbitone (veronal) despite the well-recognised toxicity of this agent and the tight regulations on its use in most countries. The use of barbitone in complement assay buffers is steeped in history, from a time when no other suitable buffers were available. This is no longer the case, encouraging us to explore alternatives to barbitone for complement assays. We compared a simple, non-toxic HEPES buffer with commercially sourced complement fixation test diluent (CFD), the "gold standard" barbitone buffer, in several clinically relevant complement activity assays and across species. In classical pathway haemolysis assays in human and non-human serum, there was no difference in haemolytic curves or calculated haemolytic activity (CH50) between CFD and an optimised HEPES buffer (HBS) supplemented with cations. Alternative pathway haemolysis assays in human serum were also identical in the two buffers. In a complement fixation test for anti-erythrocyte antibodies, complement consumption was identical for the two buffer systems. The data demonstrate that barbitone-based buffers are unnecessary for assays of complement activity and can readily be replaced with safe and simple alternatives.
Copyright © 2018 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Buffer; Complement; Complement fixation test; Haemolysis assay

Mesh:

Substances:

Year:  2018        PMID: 30033110     DOI: 10.1016/j.imbio.2018.07.016

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  11 in total

1.  Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models.

Authors:  Sarah M Carpanini; Megan Torvell; Ryan J Bevan; Robert A J Byrne; Nikoleta Daskoulidou; Takashi Saito; Takaomi C Saido; Philip R Taylor; Timothy R Hughes; Wioleta M Zelek; B Paul Morgan
Journal:  Acta Neuropathol Commun       Date:  2022-07-06       Impact factor: 7.578

2.  Analysis of complement deposition and processing on Chlamydia trachomatis.

Authors:  Mads Lausen; Mikkel Eggert Thomsen; Gunna Christiansen; Nichlas Karred; Allan Stensballe; Tue Bjerg Bennike; Svend Birkelund
Journal:  Med Microbiol Immunol       Date:  2020-11-18       Impact factor: 3.402

3.  Orally administered β-glucan improves the hemolytic activity of the complement system in horses.

Authors:  Taline Scalco Picetti; Lucas de Figueiredo Soveral; Rovian Miotto; Luana Marina Scheer Erpen; Yasmin Kreutz; João Antônio Guizzo; Rafael Frandoloso; Luiz Carlos Kreutz
Journal:  Vet World       Date:  2021-04-05

4.  Measuring Total Classical Pathway and Activities of Individual Components of the Mouse Complement Pathway.

Authors:  Wioleta M Zelek
Journal:  Bio Protoc       Date:  2021-10-05

5.  Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species.

Authors:  Wioleta M Zelek; Philip R Taylor; B Paul Morgan
Journal:  Immunology       Date:  2019-06-17       Impact factor: 7.397

6.  Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species.

Authors:  Wioleta M Zelek; B Paul Morgan
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 8.786

7.  Development of EndoScreen Chip, a Microfluidic Pre-Endoscopy Triage Test for Esophageal Adenocarcinoma.

Authors:  Julie A Webster; Alain Wuethrich; Karthik B Shanmugasundaram; Renee S Richards; Wioleta M Zelek; Alok K Shah; Louisa G Gordon; Bradley J Kendall; Gunter Hartel; B Paul Morgan; Matt Trau; Michelle M Hill
Journal:  Cancers (Basel)       Date:  2021-06-08       Impact factor: 6.575

8.  Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5.

Authors:  Wioleta M Zelek; Georgina E Menzies; Andrea Brancale; Brigitta Stockinger; Bryan Paul Morgan
Journal:  Immunology       Date:  2020-07-13       Impact factor: 7.215

9.  Novel Monoclonal Antibodies Against Mouse C1q: Characterisation and Development of a Quantitative ELISA for Mouse C1q.

Authors:  Robert A J Byrne; Megan Torvell; Nikoleta Daskoulidou; Dina Fathalla; Eirini Kokkali; Sarah M Carpanini; B Paul Morgan
Journal:  Mol Neurobiol       Date:  2021-05-18       Impact factor: 5.590

10.  A Factor H-Fc fusion protein increases complement-mediated opsonophagocytosis and killing of community associated methicillin-resistant Staphylococcus aureus.

Authors:  Megan A G Sage; Katelyn D Cranmer; Michele L Semeraro; Shelby Ma; Elena V Galkina; Y Tran; Keith L Wycoff; Julia A Sharp
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.